Patents Assigned to HEMOGENYX PHARMACEUTICALS LLC
  • Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies
    Patent number: 11945866
    Abstract: The described invention provides compositions containing bi-specific antibodies that bind to human tyrosine kinase receptor FLT3/FLK2 receptor protein and to CD3 receptor protein expressed on T-cells and use of the compositions containing the bispecific antibodies in the preparation of a medicament for eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: April 2, 2024
    Assignee: HEMOGENYX PHARMACEUTICALS LLC
    Inventor: Vladislav Sandler
  • Monoclonal antibodies to human FLT3/FLK2 receptor protein
    Patent number: 11104738
    Abstract: The described invention provides compositions containing bi-specific antibodies that bind to human tyrosine kinase receptor FLT3/FLK2 receptor protein and to CD3 receptor protein expressed on T-cells and use of the compositions containing the bispecific antibodies in the preparation of a medicament for eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: August 31, 2021
    Assignee: HEMOGENYX PHARMACEUTICALS LLC
    Inventor: Vladislav Sandler
  • METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES
    Publication number: 20210188978
    Abstract: The described invention provides compositions containing bi-specific antibodies that bind to human tyrosine kinase receptor FLT3/FLK2 receptor protein and to CD3 receptor protein expressed on T-cells and use of the compositions containing the bispecific antibodies in the preparation of a medicament for eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient.
    Type: Application
    Filed: December 23, 2020
    Publication date: June 24, 2021
    Applicant: Hemogenyx Pharmaceuticals LLC
    Inventor: Vladislav Sandler
  • Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies
    Patent number: 11021536
    Abstract: The described invention provides compositions containing bispecific antibodies that bind to human tyrosine kinase receptor FLT3/FLK2 receptor protein and to CD3 receptor protein expressed on T-cells and use of the compositions containing the bispecific antibodies in the preparation of a medicament for eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: June 1, 2021
    Assignee: HEMOGENYX PHARMACEUTICALS LLC
    Inventor: Vladislav Sandler